CASTLE BIOSCIENCES INC
Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.
MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 16,114 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $31.08 ($30.68–$31.34, $0.50M total) across 6 trades over 2026-08-04 to 2026-08-05 under a Rule 10b5-1 trading plan.
MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 22,902 shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $31.06 ($30.68–$31.34, $0.71M total) across 3 trades over 2026-08-04 to 2026-08-05 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning CSTL (CASTLE BIOSCIENCES INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CSTL coverage spans insider activity, earnings and regulation.
In the last 30 days, CSTL insiders filed 43 SEC Form 4 transactions — no purchases and 43 sales ($3.2M). The most active reporter was MAETZOLD DEREK J, Pres. & Chief Exec. Officer, with 36 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Guidance raise plus strong TissueCypher volume growth supports a bullish near-term read-through, while margin compression and DecisionDx-SCC coverage change remain key risks.
This is a routine insider sale under a pre-arranged 10b5-1 plan, with limited direct signal on near-term fundamentals.
This is a routine insider-sale disclosure with no stated operational or financial catalyst, but it can slightly affect near-term sentiment.
This is a routine, pre-arranged insider sale with no stated operational or guidance change, so near-term fundamental impact is limited.
The filing is a routine insider sale under a pre-arranged 10b5-1 plan, which is typically lower-signal than discretionary selling.
alphai scores every news story that mentions CSTL with an AI model for sentiment and relevance, and aggregates insider trades from CASTLE BIOSCIENCES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.
6 min readMAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 16,114 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $31.08 ($30.68–$31.34, $0.50M total) across 6 trades over 2026-08-04 to 2026-08-05 under a Rule 10b5-1 trading plan.
2 min readMAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 22,902 shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $31.06 ($30.68–$31.34, $0.71M total) across 3 trades over 2026-08-04 to 2026-08-05 under a Rule 10b5-1 trading plan.
2 min readJuvenal Tobin W (Chief Commercial Officer) sold 19,040 shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $29.21 ($28.25–$30.26, $0.56M total) across 4 trades over 2026-07-31 to 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readMAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 17,144 shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $30.28 ($30.15–$30.35, $0.52M total) across 2 trades over 2026-07-31 to 2026-08-03 under a Rule 10b5-1 trading plan.
2 min readCASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026earningsre.htm EX-99.1 Document Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32
6 min readCastle Biosciences (Nasdaq: CSTL) said the New York State Department of Health approved its AdvanceAD-Tx™ gene expression profile test for patients aged 12+ with moderate-to-severe atopic dermatitis. The assay is intended to classify patients into JAK inhibitor responder or Th2 molecular profiles to guide systemic therapy selection.
3 min readCastle Biosciences (Nasdaq: CSTL) said a prospective multicenter study in Dermatology and Therapy found its DecisionDx-Melanoma i31-SLNB test more accurately predicts sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogram. In 912 patients, i31-SLNB low-risk cases had 2.6% observed SLN positivity vs 5.8% for MIA; i31-SLNB AUC was 0.74 vs 0.61 (p=0.001).
3 min readMAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 278 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at $20.86 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readMAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 278 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at $20.86 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min read
